Urolithin A + SS-31: The Mitochondrial Synergy Stack for Cellular Energy Restoration

The Mitochondrial Ageing Problem

By age 50, most people have accumulated decades of mitochondrial damage. The inner mitochondrial membrane — the site of ATP production — becomes increasingly damaged by reactive oxygen species generated during normal energy metabolism. Cardiolipin, the unique phospholipid that anchors the electron transport chain complexes, oxidises and loses its structural integrity. The quality control system (mitophagy) that should clear the worst-damaged mitochondria becomes less efficient.

The result: progressively less efficient energy production, more oxidative stress, and reduced capacity for physical and cognitive performance — the classic mitochondrial ageing phenotype.

Two interventions with clinical-grade evidence address different aspects of this decline:

• Urolithin A — reactivates mitophagy to clear the irreparably damaged
• SS-31 (elamipretide) — repairs cardiolipin in existing mitochondria to restore their function

Urolithin A: The Mitophagy Reactivator

Mitophagy is the cellular quality control process that selectively destroys damaged mitochondria. The PINK1/Parkin pathway is the primary molecular machinery: PINK1 accumulates on depolarised (damaged) mitochondria, recruits Parkin, which ubiquitinates outer membrane proteins and flags the mitochondrion for autophagosomal destruction.

With age, this pathway becomes less active — damaged mitochondria accumulate rather than being cleared. Urolithin A is the most potent natural activator of PINK1/Parkin-mediated mitophagy identified to date.

^[1]

The Clinical Evidence

The Phase 2 RCT (Singh et al., Cell Metabolism, 2022) is the most compelling human evidence. 66 sedentary adults aged 65–90 were randomised to Urolithin A 500mg, 1000mg, or placebo for 4 months.

The 1000mg group showed:

• Significantly improved 6-minute walk distance (muscle endurance)
• Increased mitochondrial gene expression (OXPHOS genes, mitophagy markers)
• Reduced plasma inflammatory markers (IL-6, C-reactive protein)
• Improved muscle strength trends (not statistically significant at 4 months)

^[2]

Crucially, mitophagy biomarkers (ATG7, PINK1, LC3B) increased in muscle biopsies — confirming the mechanism is active in humans at oral doses.

SS-31: The Inner Membrane Repair Agent

SS-31 (elamipretide) is a synthetic tetrapeptide with a unique mechanism: it concentrates in the inner mitochondrial membrane with 1000x greater affinity than the cytoplasm. Once there, it binds cardiolipin — the structural phospholipid that anchors the electron transport chain complexes and ATP synthase.

Cardiolipin oxidation is one of the earliest and most consequential events in mitochondrial ageing. When cardiolipin becomes oxidised:

• Electron transport chain complexes dissociate from their optimal arrangement
• ATP synthesis efficiency drops
• Cytochrome c is released (triggering apoptosis)
• ROS production increases

SS-31 stabilises cardiolipin against oxidation, restoring electron transport chain supercomplex assembly and ATP synthesis efficiency.

^[4]

What SS-31 Cannot Do

SS-31 repairs mitochondria that are dysfunctional but structurally intact enough to benefit from membrane stabilisation. It cannot resurrect severely damaged mitochondria with compromised DNA or irreversibly damaged membrane proteins. This is precisely why the combination with Urolithin A is powerful: SS-31 maximises function in the repairable mitochondria while Urolithin A clears the ones beyond repair.

^[5]

The Synergy: Sequential and Simultaneous Action

Why these two work together:

Think of the mitochondrial pool as a fleet of vehicles. Some are old and battered but still running — these benefit from maintenance (SS-31 cardiolipin repair). Some are so damaged they are beyond repair and consume resources while producing little useful output — these should be removed (Urolithin A mitophagy). After clearing the worst ones, the remaining pool is healthier, and mitochondrial biogenesis (PGC-1α-driven) can produce fresh replacements.

SS-31 + Urolithin A creates a maintenance and quality control programme working simultaneously — repairing what can be repaired, clearing what cannot be, and enabling replacement of the cleared with new mitochondria.

^[3]

The Complete Mitochondrial Stack

Timing Protocol

SS-31 Practical Considerations

SS-31 is a research peptide with no approved oral formulation. Subcutaneous injection is the standard research protocol.

Dose range: 10–40 mg/day subcutaneous in research settings. Clinical trials used 0.05–0.25 mg/kg. A practical starting point for research use is 10 mg/day.

Sourcing requirements:

• Third-party tested for purity ≥98% (HPLC)
• Endotoxin tested (LAL negative)
• Mass spectrometry sequence verification
• Bacteriostatic water for reconstitution
• Sterile 29–31 gauge insulin syringes

Storage: Lyophilised powder at -20°C. Reconstituted at 4°C, use within 30 days.

Monitoring Mitochondrial Health

Objective biomarkers to track stack efficacy:

• Lactate/pyruvate ratio — reflects mitochondrial efficiency in energy metabolism
• VO2 max testing — most sensitive functional measure of mitochondrial capacity
• Grip strength + 6-minute walk — used in clinical trials, practical in practice
• Serum GDF-15 — mitochondrial stress marker, decreases with improved function
• NAD+ testing — confirms NMN efficacy in raising systemic NAD+

Frequently Asked Questions

Can I get the benefits of SS-31 without injecting? Current evidence does not support oral SS-31. The peptide is too large and polar for meaningful gastrointestinal absorption without delivery system enhancement. Topical and intranasal research is ongoing but no validated oral form exists.

Is Urolithin A worth it if I already eat pomegranates? Only ~40% of people have the gut microbiome to convert ellagitannins to Urolithin A. Even among converters, the conversion efficiency is highly variable. Supplementation ensures consistent delivery regardless of microbiome status.

How long before effects are measurable? Urolithin A effects on mitochondrial gene expression are measurable in biopsies within 4–8 weeks. Functional improvements (walk distance, strength) required 4 months in the RCT. SS-31 effects on cardiac function markers visible within weeks in clinical studies.

Can I take this with Rapamycin? Yes — mitophagy induction (Urolithin A) and mTOR inhibition (Rapamycin) are synergistic for cellular housekeeping. This combination is used in advanced longevity protocols.

Related Substances

• View SS-31
• View Urolithin A
• View NMN
• View MOTS-c

Related Research

• SS-31 (Elamipretide): Reversing Mitochondrial Aging at the Inner Membrane
• The Mitochondrial Synergy: Why SS-31 Must Precede MOTS-c for Maximum Effect
• NAD+ Optimization Beyond NMN: CD38 Inhibition and the Methylation Cycle
• Taurine + NMN Longevity Stack: The Anti-Aging Combination